Navigation Links
Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
Date:9/24/2008

Opening Ceremony Launches Effort to Transform Korean Pharmaceutical Industry

CHUNCHEON CITY, Korea, Sept. 24 /PRNewswire-USNewswire/ --

Civic and business officials gathered in Chuncheon City Sept. 23 to open a worldwide bioequivalence research institute operated by International Scientific Standard, Inc. (ISS), a joint venture company.

ISS, formed by Battelle and YuYu Pharma, will focus on testing the safety and efficacy of generic drugs in order to position the Korean pharmaceutical market for global sales. The ISS pledges to work closely with customers to ensure testing meets global standards.

Bioequivalence testing services begin in the fall in the GLP-compliant laboratory, which will begin operation with 10 to 20 researchers. They'll conduct the work in a 1,090-square meter facility in Chuncheon City that is equipped with state-of-the-art LC/MS equipment imported from Japan and the United States.

The opening ceremony was attended by: Kim Jin Son, Kang Won Provincial Governor; Lee Kwang Jun, Chuncheon Mayor; Dr. Carl Kohrt, Battelle President and CEO; and Dr. Seungpil Yu, Chairman of YuYu Pharma.

Officers of ISS include YuYu Pharma's Dr. Seungpil Yu, who is Chairman of the Board, and Battelle's Dr. Joan Adams, who is Representative Director.

Chuncheon City offered incentives in order to bring the ISS facility to the city because it has the potential to have a positive impact on the economy. Chuncheon estimates new drug development production could eventually reach $168 million annually and potentially create 3,000 jobs.

YuYu Inc. is a pharmaceutical company listed on the Korea Stock Exchange.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. Battelle oversees $4 billion in research and 20,400 staff members in more than 120 locations around the world.

For more information contact Public Relations Manager Katy Delaney at

(410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: